People & Places

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 7
Volume 16
Issue 7

Dr. Sarah Donaldson, Dr. Robert Kyle, Dr. Scott Lippman

Dr. Sarah Donaldson

ASCO presented the 2007 Pediatric Oncology Award to Sarah S. Donaldson, MD, professor of radiation oncology at Stanford Comprehensive Cancer Center in California. Dr. Donaldson was recognized for her work in increasing the understanding of and the cure rates for various childhood cancers. She also serves as associate chair of radiation oncology at Stanford University School of Medicine.

Dr. Robert Kyle

Robert A. Kyle, MD, professor of medicine and laboratory medicine at the Mayo Medical School, Rochester, Minnesota, was awarded the David A. Karnofsky Memorial Award at ASCO 2007 for his extensive research in hematology. He is director of the Scientific Advisory Board for the International Myeloma Foundation and chairman of ECOG's Myeloma Committee.

Dr. Scott Lippman

The American Cancer Society Award was given to Scott M. Lippman, MD, at ASCO 2007 in recognition of his work in cancer prevention. Dr. Lippman chairs the Department of Clinical Cancer Prevention at M.D. Anderson Cancer Center and is professor of both clinical cancer prevention and thoracic/head and neck medical oncology. His research interests are focused on translational chemoprevention studies.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content